产品
编 号：F348336
分子式：C147H238N44O42S
分子量：3325.8
分子式：C147H238N44O42S
分子量：3325.8
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 40077-57-4
产品详情
生物活性：
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.
体内研究：
Aviptadil (500 μg/kg; 静脉注射; 每隔一天一次; 三周) 在 Sprague Dawley 大鼠模型中能完全预防并显著逆转 Monocrotaline (MCT) (HY-N0750) 诱导的肺动脉高压 ((Pulmonary Arterial Hypertension (PAH))。Aviptadil 与 Bosentan (HY-A0013) 具有协同作用.Aviptadil (150 μg/kg/d; 腹腔灌胃; 2.5 μl/h; 4周) 在 Sprague-Dawley 大鼠中可以消除支气管高反应性（BHR），具有支气管扩张的特性.Aviptadil (0.1, 3μg/kg ; 静脉注射) 在大鼠肺移植模型中可改善活体大鼠肺移植模型再灌注损伤(reperfusion injury).Animal Model:Sprague Dawley rats
Dosage:Bosentan (HY-A0013 ) 300 mg/kg, Aviptadil 500 μg/kg
Administration:Bosentan (HY-A0013 ) Oral gavage (p.o); AviptadilIntraperitoneal injection (i.p)
Result:Starting on day 21, the rats treated with Bosentan or Aviptadilalone had a 29% reduction in mortality (P< 0.0001). No death was observed in the rats during the same time period.
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.
体内研究：
Aviptadil (500 μg/kg; 静脉注射; 每隔一天一次; 三周) 在 Sprague Dawley 大鼠模型中能完全预防并显著逆转 Monocrotaline (MCT) (HY-N0750) 诱导的肺动脉高压 ((Pulmonary Arterial Hypertension (PAH))。Aviptadil 与 Bosentan (HY-A0013) 具有协同作用.Aviptadil (150 μg/kg/d; 腹腔灌胃; 2.5 μl/h; 4周) 在 Sprague-Dawley 大鼠中可以消除支气管高反应性（BHR），具有支气管扩张的特性.Aviptadil (0.1, 3μg/kg ; 静脉注射) 在大鼠肺移植模型中可改善活体大鼠肺移植模型再灌注损伤(reperfusion injury).Animal Model:Sprague Dawley rats
Dosage:Bosentan (HY-A0013 ) 300 mg/kg, Aviptadil 500 μg/kg
Administration:Bosentan (HY-A0013 ) Oral gavage (p.o); AviptadilIntraperitoneal injection (i.p)
Result:Starting on day 21, the rats treated with Bosentan or Aviptadilalone had a 29% reduction in mortality (P< 0.0001). No death was observed in the rats during the same time period.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备